{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.5-mg+Ranibizumab",
    "query": {
      "intervention": "0.5-mg Ranibizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.5-mg+Ranibizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T11:30:31.036Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01469156",
      "title": "Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Polypoidal Choroidal Vasculopathy"
      ],
      "interventions": [
        {
          "name": "ranibizumab 0.5 or 2.0 mg/0.05 cc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Southeast Retina Center, Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 1,
      "location_summary": "Augusta, Georgia",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01469156"
    },
    {
      "nct_id": "NCT00593450",
      "title": "Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Age Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 1208,
      "start_date": "2008-02",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 59,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593450"
    },
    {
      "nct_id": "NCT06771271",
      "title": "A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema",
        "Uveitic Macular Edema"
      ],
      "interventions": [
        {
          "name": "RO7200220",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2019-07-22",
      "completion_date": "2023-11-13",
      "has_results": false,
      "last_update_posted_date": "2025-01-13",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 19,
      "location_summary": "Beverly Hills, California • Oxnard, California • Palm Desert, California + 16 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06771271"
    },
    {
      "nct_id": "NCT02530918",
      "title": "Study of DS-7080a for the Treatment of Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration",
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "DS-7080a",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2015-07",
      "completion_date": "2018-01-02",
      "has_results": false,
      "last_update_posted_date": "2018-05-09",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02530918"
    },
    {
      "nct_id": "NCT01464723",
      "title": "Study EvAluating Genotypes While Using Lucentis 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2008-05",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2019-08-14",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464723"
    },
    {
      "nct_id": "NCT02543229",
      "title": "Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Eye Diseases",
        "Macular Degeneration",
        "Retinal Diseases",
        "Retinal Degeneration",
        "Neovascularization, Pathologic"
      ],
      "interventions": [
        {
          "name": "OPT-302",
          "type": "DRUG"
        },
        {
          "name": "Lucentis™",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opthea Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2015-07",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02543229"
    },
    {
      "nct_id": "NCT00676559",
      "title": "Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "Efalizumab",
          "type": "DRUG"
        },
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2016-08-26",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 10,
      "location_summary": "Tucson, Arizona • San Diego, California • Torrance, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Bangor",
          "state": "Maine"
        },
        {
          "city": "South Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00676559"
    },
    {
      "nct_id": "NCT06571045",
      "title": "A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Macular Edema (DME)"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "EYE103",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyeBiotech Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 984,
      "start_date": "2024-08-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 85,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 78 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06571045"
    },
    {
      "nct_id": "NCT02698566",
      "title": "A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2016-03-21",
      "completion_date": "2016-04-05",
      "has_results": true,
      "last_update_posted_date": "2017-09-21",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 4,
      "location_summary": "Paducah, Kentucky • Charlotte, North Carolina • Chattanooga, Tennessee + 1 more",
      "locations": [
        {
          "city": "Paducah",
          "state": "Kentucky"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02698566"
    },
    {
      "nct_id": "NCT01251978",
      "title": "Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Choroidal Melanoma"
      ],
      "interventions": [
        {
          "name": "Ranibizumab 2 mg",
          "type": "DRUG"
        },
        {
          "name": "0.5 mg Ranibizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New England Retina Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 10,
      "start_date": "2010-07",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-09-29T11:30:31.036Z",
      "location_count": 1,
      "location_summary": "Hamden, Connecticut",
      "locations": [
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251978"
    }
  ]
}